LianBio Promotes Pascal Qian to Chief Commercial Officer
April 21 2023 - 8:15AM
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to
bringing innovative medicines to patients in China and other major
Asian markets, today announced the promotion of Pascal Qian to the
position of Chief Commercial Officer. He will continue to also
serve as the company’s China General Manager.
“As we continue to prepare for potential mavacamten approval and
launch in 2024, Pascal will oversee the significant growth of our
commercial capabilities in his expanded role of Chief Commercial
Officer and China General Manager,” said Yizhe Wang, Ph.D., Chief
Executive Officer of LianBio. “With Pascal’s track record building
our business strategy and infrastructure, as well as his extensive
experience launching important medicines, we are confident that
LianBio is well positioned to enter the commercial market in
China.”
Pascal Qian has more than 25 years of experience in the China
biopharmaceutical industry and a robust track record of driving
revenue growth and building successful commercial teams. He has
launched multiple drugs in the region, including Verzenio, Tyvyt,
Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair. Mr. Qian
has served as LianBio’s China General Manager since July 2021. In
his expanded role as Chief Commercial Officer, he will lead the
company’s commercial strategy and readiness, in addition to
managing China operations.
Prior to joining LianBio, Mr. Qian served as the Vice President,
Head of Oncology Business Unit, at Lilly China. In this capacity,
he oversaw a more than 700-person China Oncology BU team and was
responsible for the group’s P&L and organizational development.
Prior to Lilly, Mr. Qian held roles at Novartis from 2012 until
2018, ultimately serving as Executive Director, BU Head of Solid
Tumor at Novartis Oncology. From 2005 until 2012, he served in
several key roles of increasing responsibility at Pfizer, including
Business Liaison Head, Global Clinical Development and Medical
Affairs, and China Oncology and Ophthalmology Business Unit
Head.
“LianBio is poised to bring our first drug to market in China
next year and make a meaningful impact for patients,” said Mr.
Qian. “I’m proud of the team we’ve assembled and look forward to
continue growing our commercial capabilities and act on our
long-term growth opportunities.”
About LianBioLianBio is a cross-border
biotechnology company on a mission to bring transformative
medicines to historically underserved patients in China and other
Asian markets. Through partnerships with highly innovative
biopharmaceutical companies around the world, LianBio is advancing
a diversified portfolio of clinically validated product candidates
with the potential to drive new standards of care across
cardiovascular, oncology, ophthalmology, and inflammatory disease
indications. LianBio is establishing an international
infrastructure to position the company as a partner of choice with
a platform to provide access to China and other Asian markets. For
more information, please visit www.lianbio.com.
Cautionary Note Regarding Forward-Looking
Statements Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
forward-looking statements. The words “anticipate,” “believe,”
“continue,” “estimate,” “potential,” “expect,” “may,” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Forward-looking statements in this press release
include, but are not limited to, statements concerning the
company’s preparations and positioning to become a commercial-stage
company, the Company’s expectations in 2024 with regards to the
approval and launch of mavacamten in China and its ability to
impact patients throughout client, and the Company’s plans to build
out its commercial infrastructure. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the Company’s
ability to successfully initiate and conduct its planned clinical
trials and complete such clinical trials and obtain results on its
expected timelines, or at all; the Company’s plans to leverage data
generated in its partners’ global registrational trials and
clinical development programs to obtain regulatory approval and
maximize patient reach for its product candidates; the Company’s
ability to identify new product candidates and successfully acquire
such product candidates from third parties; competition from other
biotechnology and pharmaceutical companies; general market
conditions; the impact of changing laws and regulations and those
risks and uncertainties described in LianBio’s filings with the
U.S. Securities and Exchange Commission (SEC), including LianBio’s
Annual Report on Form 10-K for the year ended December 31, 2022
filed with the SEC on March 28, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and LianBio specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise.
Readers should not rely upon this information as current or
accurate after its publication date.
For investor inquiries, please contact:
Elizabeth Anderson, VP Communications and Investor
Relations E:
elizabeth.anderson@lianbio.comT: +1 646 655
8390
For media inquiries, please contact:
Josh Xu, Director of Communications
E: josh.xu@lianbio.com T: +86 136
6140 8315
Katherine Smith, Evoke
CanaleE: katherine.smith@evokegroup.comT: +1
619 849 5378
LianBio (NASDAQ:LIAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
LianBio (NASDAQ:LIAN)
Historical Stock Chart
From Jul 2023 to Jul 2024